News

MarketBeat on MSN4h
Is It Time to Buy the Dip in Novo Nordisk Stock?
CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Fierce Biotech1d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Money Morning20h
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
STAT1d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
BioSpace1d
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...